Please login to the form below
rFIXFc
This page shows the latest rFIXFc news and features for those working in and with pharma, biotech and healthcare.
FDA starts review of Biogen Idec's haemophilia A therapy
Eloctate was developed in partnership with Swedish Orphan Biovitrum (Sobi), which also collaborated on the development of Biogen Idec's haemophilia B candidate Alprolix (recombinant factor IX Fc fusion protein; rFIXFc).
Latest news
-
Biogen submits haemophilia drug for US approval
Backing the submission of rFIXFc are results from B-LONG, which Biogen says is the largest phase III clinical study in haemophilia B to date. ... This study demonstrated that rFIXFc was both clinically effective and safe, helping to prevent bleeding
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Graphite
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
